ILLUMINATION IN HUMAN AGING: SLEEP AND MOOD EFFECTS

描述（改编自研究者摘要）：大多数美国老年人 受轻度抑郁或睡眠障碍困扰，这通常是 紧密交织在一起在AG 12364的前5年，他们一直在 研究老年志愿者抑郁和失眠的病因。他们的 研究结果表明，一个令人震惊的程度的昼夜节律不同步， 这可能解释了他们失眠和情绪低落的部分原因。 此外，他们的志愿者表现出令人惊讶的弱昼夜节律和临床症状。 对4天强光处理的反应，表明可能的光 阻力在这次更新中，他们将测试更多的延长4周的强光 在家里进行治疗，以确定志愿者年龄的光抵抗力 60-79岁可以通过更长的治疗时间来克服。一百 将招募50名患有严重抑郁症的志愿者， 一项由为期一周的安慰剂基线（以半夜睡眠结束）组成的试验 剥夺，随后随机分配至10，000 lux白色组4周 光或10勒克斯红光安慰剂。基线期间的相位分型将决定 在随机化之前，是否最好在早晨给予治疗， 中午或晚上。将对6-硫酸氧褪黑激素的部分尿液样本进行 基线结束时采集48小时， 随机治疗，以确定10，000勒克斯治疗是否成功 使不同步的昼夜节律相位调整正常化。的成功 降低GDS抑郁评分和减少睡眠投诉的治疗 将被审查。

DESCRIPTION (adapted from investigator's abstract): Most older Americans are troubled by low-level depression or sleep disturbances, which are often intimately intertwined. In the first 5 years of AG12364, they have been examining the etiologies of depression and insomnia in aging volunteers. Their findings suggest an appalling degree of circadian malsynchronization among aging Americans, which possibly explains part of their insomnia and low mood. Further, their volunteers displayed surprisingly weak circadian and clinical responses to 4 days of bright light treatment, indicating possible light resistance. In this renewal, they will test more extended 4-week bright light treatments in the home, to determine if light resistance in volunteers ages 60-79 years can be overcome with a longer duration of treatment. One hundred fifty volunteers with significant depressive complaints will be recruited for a trial consisting of one-week placebo baseline terminating in a half-night sleep deprivation, followed by 4 weeks randomized assignment to 10,000 lux white light or 10 lux red light placebo. Phase-typing during baseline will determine before randomization whether treatment should best be given in the morning, mid-day, or evening. Fractional urine samples for 6-sulphatoxymelatonin will be collected for 48 hours at the end of baseline and for 48 hours at the end of the randomized treatment, to determine if 10,000 lux treatments successfully normalize malsynchronized circadian phase adjustments. The success of the treatment in lowering the GDS depression score and in reducing sleep complaints will be examined.